Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Asset

Classes

Type

Transaction Type

Asset Class I

The Journal 3/3/2020 Views 1,723,051

Valuation [$40M] done by Joel on Alex WP Data

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

Copyright Law

B2B & B2B & B2C

Asset Class II

16 volumes

Valuation [$5M] done by Joel & Aviva

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

Copyright Law

B2B & B2B & B2C

Asset Class III

eProceedings https://pharmaceuticalint elligence.com/2019- vista/e-proceedings-and- tweet-collections-per- conference-2013-2020- viewsdownloads-x-100- real-time-coverage-of- 60-events-by-ala-sjw/

60 events Valuation [$1.4M]

done by Dr. Williams &

Aviva

Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia

Copyright Law

B2B & B2B & B2C

Asset Class IV

Platform, composition of methods and workflows for the content creation of scientific curations

TBD

Copyright Law and Proprietary Knowhow

internal and contracts

Asset

Classes

Transaction Type

Asset Class V

Gallery of Biological Images in use in Articles and Books

TBD

Artifacts in the of Content Creation of PRIOR ART

in original curations

Asset Class VI

Team of Experts

BIOs Final Improvement Team (FIT)

Factor of Content Creation

Internal

Asset Class VII

Royalties on BioMed e- Series:Page downloads, Book borrowings and Book sale

111,645 page downloads in total on 3/9/2020

Current Account Receivables

Royalties Agreement with KDP

@Amazon

Pages download in 16 books

Asset Class VIII

Subscribers to the Website

2,554 on 3/29/2020

Potential Account Receivables

n/a

Drivers of Loyalty & Success

Asset Class IX

INTANGIBLE ASSETS

& Intrinsic Value = Good Will

TBD

Potential Account Receivables

Copyright Law

External

e-Reputation

e-VOICE PODCASTS

Audio Library

TBD

Potential Account Receivables

Copyright Law

B2B & B2B & B2C

Classes

Asset Classes

Unique Selling Point

Asset Class I

We create a new level of knowledge that is current and lively on the current issues and based on a discussion of multiple KOL

Legal, regulatory, Pharma R&D, Non academia, Gov, Journalists, media, Premium audience

academics, students, science addicts

Current high level accessible knowledge

Asset Class II

in depth as of day of publication knowledge collection of topic, background, good as a course or a journal club guide. State of the art, science based, outcome oriented KOL based perspective.

Legal, regulatory, pharma R&D, non academia, Gov, journalists and media, premium audience

Universities, Patient advocacy groups, Professional associations, Curriculum developers

current highly multiple domain specialized accessible knowledge

Asset Class III

In depth on publication day, knowledge collection of topic, depicts event spirit and highlights with KOL perspective and annotation, scientific documents and historical state of Science

Global Biotech & Healthcare Conference Organizers + Customers of Asset Class I+II

Conference Participants, Future Attendees & Participants Missing Conference Sessions

Real time, On demand, Event Tweet Collections

Asset Class IV

New topics, new geographies knowledge community makers, LPBI new products pipeline

the global KOL community in health, life- sciences and pharma

unique, easy, proven, state of the art

Selection done by Domain Experts for IP creation of original content

TBD

e-Readers, Publishers, Future Publishing Academics

Asset Class VI

Group of outcome-oriented KOLs in Health Care & Pharma Industry & Academia expertise

Human Capital asset

Global reach

e-Readers of Science e-Books

Scientist- contributors on FIT and Past contributors

A reach into the top of the line Executives and KOLs in Pharma and Life sciences R&D

To be segmented and Targeted for Outreach and Outbound Marketing

Venture Owner

Asset Class IX

Product/Service Quality & Reputation

Acquirer and Its Customers

Asset Class X

Selection of most prominent Figures to be featured

Media Licensing Agreements

PBS, TV

Networks